Kips Bay Medical Announces Clinical Trial in Europe for the FDA
Kips Bay Medical, Inc. (NASDAQ: KIPS) along with Manny Villafa, its Founder, Chairman and CEO, announced today that its U.S. feasibility trial (eMESH I) of the eSVS Mesh has commenced in Bern, Switzerland and anticipates first implants and enrollments under this study to begin the week of September 2, 2012. The objective of the eMESH I study remains the demonstration of initial safety and performance of the Kips Bay Medical eSVS Mesh sufficient to allow the FDA to approve an IDE for a pivotal study.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.